Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2799MR)

This product GTTS-WQ2799MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2799MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9873MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ6836MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ1260MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ2361MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ10388MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ2781MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ1011MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ15742MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW